Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Operating Leases (2022 - 2026)

HeartSciences (HSCS) has disclosed Operating Leases for 4 consecutive years, with $314527.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Operating Leases fell 27.54% year-over-year to $314527.0, compared with a TTM value of $314527.0 through Apr 2025, down 27.54%, and an annual FY2025 reading of $314527.0, down 27.54% over the prior year.
  • Operating Leases was $314527.0 for Q2 2025 at HeartSciences, down from $405743.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $583016.0 in Q1 2023 and bottomed at $314527.0 in Q2 2025.
  • Average Operating Leases over 4 years is $472825.4, with a median of $486885.0 recorded in 2023.
  • The sharpest move saw Operating Leases decreased 11.35% in 2023, then dropped 27.54% in 2025.
  • Year by year, Operating Leases stood at $549227.0 in 2022, then dropped by 11.35% to $486885.0 in 2023, then dropped by 16.67% to $405743.0 in 2024, then decreased by 22.48% to $314527.0 in 2025.
  • Business Quant data shows Operating Leases for HSCS at $314527.0 in Q2 2025, $405743.0 in Q3 2024, and $434045.0 in Q2 2024.